Million-Dollar Drugs: Encouraging News for Patients with Rare Diseases, But at What Cost?

In recent years, there has been some good news for many of the 30 million people in the U.S. diagnosed with a rare disease, in the form of long-awaited treatment for a number of specific conditions — but this progress has come at a staggering cost for these prescription medications. Fortunately, a new company focusing on life sciences — AEVOLVE AG — has a plan to support medical research that will benefit millions of others with rare diseases, without the alarming costs that are currently associated with drugs of this kind.

New Blockchain Models for Medical Financing: Why Aevolve is at the Forefront

Burdened by declining productivity and innovation, biopharma is seeking new ways of financing its growing needs. According to the Tufts Center for the study of Drug Development (CSDD), the cost to develop a new prescription drug is pegged at $2.6 billion. This marks a 145% increase from 2003 estimates, according to an article republished on Scientific American.

New Research Into Rare Diseases To Be Supported by Aevolve

Rogelio Santos, Jr., CEO of Aevolve, a new platform dedicated to supporting innovative medical research, recently commented on the disturbing gap that exists between the millions of people who have been diagnosed with a rare disease and the life-saving medical treatment they are currently lacking. “Shockingly, 95% of all rare diseases today have absolutely no treatment.